416 related articles for article (PubMed ID: 29643011)
21. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.
Zheng L; Bosch RJ; Chan ES; Read S; Kearney M; Margolis DM; Mellors JW; Eron JJ; Gandhi RT;
Antivir Ther; 2013; 18(1):39-43. PubMed ID: 22914318
[TBL] [Abstract][Full Text] [Related]
22. Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Griesel R; Zhao Y; Simmons B; Omar Z; Wiesner L; Keene CM; Hill AM; Meintjes G; Maartens G
Lancet HIV; 2023 Jul; 10(7):e433-e441. PubMed ID: 37230101
[TBL] [Abstract][Full Text] [Related]
23. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ;
Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629
[TBL] [Abstract][Full Text] [Related]
24. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
[TBL] [Abstract][Full Text] [Related]
25. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
Gandhi RT; Zheng L; Bosch RJ; Chan ES; Margolis DM; Read S; Kallungal B; Palmer S; Medvik K; Lederman MM; Alatrakchi N; Jacobson JM; Wiegand A; Kearney M; Coffin JM; Mellors JW; Eron JJ;
PLoS Med; 2010 Aug; 7(8):. PubMed ID: 20711481
[TBL] [Abstract][Full Text] [Related]
26. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
27. Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals.
Morón-López S; Navarro J; Jimenez M; Rutsaert S; Urrea V; Puertas MC; Torrella A; De Clercq L; Ribas BP; Gálvez C; Salgado M; Vandekerckhove L; Blanco J; Crespo M; Martinez-Picado J
Clin Infect Dis; 2019 Sep; 69(8):1320-1328. PubMed ID: 30590412
[TBL] [Abstract][Full Text] [Related]
28. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Amuge P; Lugemwa A; Wynne B; Mujuru HA; Violari A; Kityo CM; Archary M; Variava E; White E; Turner RM; Shakeshaft C; Ali S; Nathoo KJ; Atwine L; Liberty A; Bbuye D; Kaudha E; Mngqibisa R; Mosala M; Mumbiro V; Nanduudu A; Ankunda R; Maseko L; Kekitiinwa AR; Giaquinto C; Rojo P; Gibb DM; Turkova A; Ford D;
Lancet HIV; 2022 Sep; 9(9):e638-e648. PubMed ID: 36055295
[TBL] [Abstract][Full Text] [Related]
29. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.
Reynolds SJ; Makumbi F; Newell K; Kiwanuka N; Ssebbowa P; Mondo G; Boaz I; Wawer MJ; Gray RH; Serwadda D; Quinn TC
Lancet Infect Dis; 2012 Jun; 12(6):441-8. PubMed ID: 22433279
[TBL] [Abstract][Full Text] [Related]
30. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
Blanco JL; Rojas J; Paredes R; Negredo E; Mallolas J; Casadella M; Clotet B; Gatell JM; de Lazzari E; Martinez E;
J Antimicrob Chemother; 2018 Jul; 73(7):1965-1971. PubMed ID: 29608685
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Gatell JM; Kumar PN; Rockstroh JK; Schechter M; Markowitz M; Yeni P; Loutfy MR; Lazzarin A; Lennox JL; Strohmaier KM; Wan H; Barnard RJ; Nguyen BY; Teppler H;
Lancet Infect Dis; 2013 Jul; 13(7):587-96. PubMed ID: 23664333
[TBL] [Abstract][Full Text] [Related]
32. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
Joly V; Burdet C; Landman R; Vigan M; Charpentier C; Katlama C; Cabié A; Benalycherif A; Peytavin G; Yeni P; Mentre F; Argoud AL; Amri I; Descamps D; Yazdanpanah Y;
J Antimicrob Chemother; 2019 Mar; 74(3):739-745. PubMed ID: 30476165
[TBL] [Abstract][Full Text] [Related]
33. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.
Krupitsky E; Blokhina E; Zvartau E; Verbitskaya E; Lioznov D; Yaroslavtseva T; Palatkin V; Vetrova M; Bushara N; Burakov A; Masalov D; Mamontova O; Langleben D; Poole S; Gross R; Woody G
Lancet HIV; 2019 Apr; 6(4):e221-e229. PubMed ID: 30880163
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir.
Meireles MV; Pascom ARP; Duarte EC; McFarland W
AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860
[TBL] [Abstract][Full Text] [Related]
35. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Eron JJ; Rockstroh JK; Reynes J; Andrade-Villanueva J; Ramalho-Madruga JV; Bekker LG; Young B; Katlama C; Gatell-Artigas JM; Arribas JR; Nelson M; Campbell H; Zhao J; Rodgers AJ; Rizk ML; Wenning L; Miller MD; Hazuda D; DiNubile MJ; Leavitt R; Isaacs R; Robertson MN; Sklar P; Nguyen BY;
Lancet Infect Dis; 2011 Dec; 11(12):907-15. PubMed ID: 21933752
[TBL] [Abstract][Full Text] [Related]
36. Similar efficacy and safety of dolutegravir between age groups of HIV-1-infected paediatric and young adult patients aged 5 years and older.
Frange P; Avettand-Fenoel V; Veber F; Blanche S
HIV Med; 2019 Sep; 20(8):561-566. PubMed ID: 31140725
[TBL] [Abstract][Full Text] [Related]
37. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
38. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.
Castagna A; Rusconi S; Gulminetti R; Bonora S; Mazzola G; Quiros-Roldan ME; De Socio GV; Ladisa N; Carosella S; Cattelan A; Di Giambenedetto S; Mena M; Poli A; Galli L; Riva A;
AIDS; 2019 Jun; 33(7):1256-1260. PubMed ID: 30870194
[TBL] [Abstract][Full Text] [Related]
39. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
